Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 2.6 CAD 0.78% Market Closed
Market Cap: 119.5m CAD
Have any thoughts about
Theratechnologies Inc?
Write Note

Theratechnologies Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Theratechnologies Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Theratechnologies Inc
TSX:TH
Long-Term Debt
$36.5m
CAGR 3-Years
-13%
CAGR 5-Years
-6%
CAGR 10-Years
12%
B
Bright Minds Biosciences Inc
CNSX:DRUG
Long-Term Debt
CA$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ESSA Pharma Inc
NASDAQ:EPIX
Long-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Long-Term Debt
$66m
CAGR 3-Years
N/A
CAGR 5-Years
194%
CAGR 10-Years
N/A
Covalon Technologies Ltd
XTSX:COV
Long-Term Debt
CA$412.7k
CAGR 3-Years
-42%
CAGR 5-Years
N/A
CAGR 10-Years
-4%
Spectral Medical Inc
TSX:EDT
Long-Term Debt
CA$404k
CAGR 3-Years
-7%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
No Stocks Found

Theratechnologies Inc
Glance View

Market Cap
119.5m CAD
Industry
Biotechnology

Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).

TH Intrinsic Value
6.42 CAD
Undervaluation 60%
Intrinsic Value
Price

See Also

What is Theratechnologies Inc's Long-Term Debt?
Long-Term Debt
36.5m USD

Based on the financial report for Aug 31, 2024, Theratechnologies Inc's Long-Term Debt amounts to 36.5m USD.

What is Theratechnologies Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
12%

Over the last year, the Long-Term Debt growth was 5 233%. The average annual Long-Term Debt growth rates for Theratechnologies Inc have been -13% over the past three years , -6% over the past five years , and 12% over the past ten years .

Back to Top